Jupiter NeurosciencesJUNS -25.00%4 Pretax Margin % is -10,852.63% as of Mar. 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Jupiter Neurosciences ranks worse than 95.55% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Jupiter Neurosciences Pretax Margin % Related Terms
Jupiter Neurosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Jupiter Neurosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JUNS vs ZEOX, LEXX, GDTC: Pretax Margin % Comparison
For the Biotechnology subindustry, Jupiter Neurosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jupiter Neurosciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Jupiter Neurosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jupiter Neurosciences (JUNS) has a Pretax Margin % of -10,852.63% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jupiter Neurosciences and its competitors. According to the industry distribution chart, Jupiter Neurosciences ranks #902 out of 944 companies in the Biotechnology industry, placing it in the top 95.6%.
Is Jupiter Neurosciences' Pretax Margin % too high?
Jupiter Neurosciences' current Pretax Margin % is -10,852.63%. Based on the distribution chart, Jupiter Neurosciences ranks #902 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Pretax Margin % compare to ZEOX and LEXX?
According to the Biotechnology industry distribution chart, Jupiter Neurosciences ranks #902 out of 944 companies for Pretax Margin %. This places Jupiter Neurosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Pretax Margin % is -10,852.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Pretax Margin % of -10,852.63%. The current Pretax Margin % is -10,852.63%. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Pretax Margin % is -10,852.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score
Get the complete analysis for JUNS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUNS has been successfully added to your 
